Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4500+0.1400 (+10.69%)
At close: 04:00PM EDT
1.4800 +0.03 (+2.07%)
After hours: 04:16PM EDT
Advertisement

Galera Therapeutics, Inc.

2 West Liberty Boulevard
Suite 100
Malvern, PA 19355
United States
610 725 1500
https://www.galeratx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Dr. J. Mel SorensenCEO, Pres & Director902.25kN/A1957
Dr. Robert A. Beardsley M.B.A., Ph.D.Co-Founder & COO627.52kN/A1962
Mr. Christopher DegnanChief Financial Officer636.2kN/A1980
Dr. Dennis P. Riley Ph.D.Chief Scientific Officer, EmeritusN/AN/AN/A
Ms. Jennifer Evans Stacey Esq.Chief Legal & Compliance Officer and Sec.N/AN/A1965
Dr. Jon T. Holmlund M.D.Chief Medical OfficerN/AN/A1957
Mr. Mark J. Bachleda M.B.A., Pharm.D.Chief Commercial OfficerN/AN/A1975
Ms. Andie CollierSr. VP of Regulatory AffairsN/AN/AN/A
Ms. Judy SchnyderSr. VP of Clinical Operations & Data ManagementN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Corporate Governance

Galera Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement